Mounjaro Outperforms Wegovy in Weight-Loss Trial Results

Malaga, Spain – A recent clinical trial has revealed that Mounjaro is more effective than its competitor Wegovy in aiding weight loss. The trial monitored 750 obese participants for 72 weeks, concluding that those who received Mounjaro experienced an average weight loss of 20%, compared to 14% for those taking Wegovy.

This trial, funded by Eli Lilly, the manufacturer of Mounjaro, aimed to clarify the effectiveness of the two popular weight-loss medications. Mounjaro, known chemically as tirzepatide, works by targeting two appetite-regulating hormones in the brain, whereas Wegovy, or semaglutide, mimics just one. Both drugs help users feel fuller and reduce overall food intake.

Dr. Louis Aronne, who led the trial at Weill Cornell Medicine in New York, noted, “The majority of people with obesity will do just fine with semaglutide, but those at the higher end may ultimately do better with tirzepatide.” The study’s results were presented at the European Congress on Obesity.

With the average participant in the trial weighing around 113 kg (approximately 18 stone), the findings could bring significant changes to weight-loss strategies. Among participants, 32% lost at least a quarter of their body weight with Mounjaro, while only 16% achieved similar results with Wegovy.

Participants also reported improvements in health markers, with those on Mounjaro showing better blood pressure, blood sugar, and cholesterol levels. However, both medications had similar side effects.

Professor Naveed Sattar from the University of Glasgow highlighted that the availability of both drugs in the UK offers patients viable options. He remarked, “Tirzepatide sales privately are now well ahead of semaglutide, and this paper will accelerate that, I imagine.”

Wegovy, while effective for weight loss, is also approved for preventing cardiovascular issues, a benefit not yet established for Mounjaro. The ongoing research into various weight-loss medications, including alternative administration methods and new formulations, suggests that the competition in this field is far from over.

“We may be approaching the point where obesity prevention may also be possible soon,” Sattar said. “However, it would be far better to make our society healthier to prevent more people from developing obesity.”